| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Cue Biopharma, Inc.'s insiders have reduced their positions by a net 86,790 shares worth roughly $2.4M. In the past 30 days, 0 insiders bought and 3 sold.
All 3 insiders who sold still hold shares after their sales.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 694.9K | $14.50M | -11,087 | |
| Other | 116.7K | $2.43M | -1,844 | |
| VP | 47.8K | $997.5K | -1,144 | |
| Dir | 32.6K | $679.9K | - | |
| Other | 31.5K | $657.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2018 | Christopher A Marlett | Director | Buy | 7,543 | $4.86 | $36,658.98 | New | |
| Aug 29, 2018 | Kerri-Ann Millar | Vp-finance | Buy | 1,000 | $8.48 | $8,480.00 | New | |
| Aug 16, 2018 | Daniel R Passeri | CEO and President | Buy | 6,000 | $8.09 | $48,510.00 | +14.4% | |
| Jun 29, 2018 | Daniel R Passeri | CEO and President | Buy | 1,600 | $11.97 | $19,152.00 | +4.0% | |
| Dec 27, 2017 | Kenneth Pienta | Chief Medical Officer | Buy | 2,000 | $7.50 | $15,000.00 | New |